BioMedReports.Com's news report on CEL-SCI's key developments

Sep 17 2009

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special news report on key developments at CEL-SCI Corporation (NYSE Amex: CVM).

In a series of news making headlines the company has positioned themselves to quickly capitalize on opportunities in not only the H1N1 Flu space with backing from the FDA, but they have also now raised enough money to move ahead with the company's long awaited and highly anticipated PHASE III trials of their flagship cancer treatment, Multikine® -- a first of its kind immunotherapeutic agent being developed as a standard of care cancer treatment which analysts believe will attain "blockbuster drug" status.

For better or worse, news of the company's novel H1N1 flu treatment for already infected patients has pushed CEL-SCI to one of the heaviest traded sectors in the biotech market. The company is officially a "swine flu play," but it seems investors are not as easily willing to part with their shares since getting yesterday's FDA go-ahead validation. Has CEL-SCI managed to set themselves apart in a field of populous pretenders touting less impressive technologies?

In the report, company CEO, Geert Kersten says: "Many people think that all this news about H1N1 vaccines being approved is a good thing and that the danger posed by swine flu is no longer something to worry about, but nothing could be further from the truth.

"A great many people in the medical community and in the government are still very worried -- especially since new poll data shows that many people are afraid to take the new vaccines and over 80% of them don't plan to. That will pose some serious issues. That's why we're dealing with a treatment option and that's why the FDA has been very receptive to what we're doing."